Skye Bioscience (SKYE) News Today → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free SKYE Stock Alerts $13.00 0.00 (0.00%) (As of 04/29/2024 06:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSkye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meetingglobenewswire.com - April 30 at 7:00 AMSkye Bioscience to Present at Upcoming Investment Conferencesglobenewswire.com - April 23 at 7:00 AMHead-To-Head Comparison: Skye Bioscience (SKYE) versus Its Rivalsamericanbankingnews.com - April 22 at 2:14 AMSkye Bioscience (SKYE) vs. Its Rivals Financial Reviewamericanbankingnews.com - April 20 at 2:16 AMThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?investorplace.com - April 19 at 2:30 PMSkye Bioscience Inc Ordinary Sharesmorningstar.com - April 18 at 4:05 PMThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?investorplace.com - April 16 at 1:19 PMSkye Bioscience (OTCMKTS:SKYE) Coverage Initiated by Analysts at Oppenheimermarketbeat.com - April 12 at 8:23 AMSkye Bioscience, Inc.: Skye Bioscience Uplists to The Nasdaq Global Marketfinanznachrichten.de - April 10 at 12:44 PMSkye Bioscience Uplists to The Nasdaq Global Marketglobenewswire.com - April 10 at 8:00 AMSkye Bioscience, Inc. (OTCMKTS:SKYE) Short Interest Updatemarketbeat.com - March 27 at 9:50 PMMercedes Mone Drops Julia Hart, Willow Nightingale Gets Main Event Win On AEW Dynamitemsn.com - March 15 at 12:52 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Guardant Health (GH), Cue Health (HLTH) and Skye Bioscience (OtherSKYE)markets.businessinsider.com - March 14 at 2:51 PMSkye Bioscience, Inc. (OTCMKTS:SKYE) Sees Significant Growth in Short Interestmarketbeat.com - March 13 at 5:57 PMSkye Bioscience, Inc.: Skye Bioscience Announces $40 Million Private Placement Equity Financingfinanznachrichten.de - March 13 at 2:09 PMAll Three of Our Analysts Agreeinvestorplace.com - March 8 at 8:02 PMSkye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directorsglobenewswire.com - March 4 at 7:00 AMSkye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertensionglobenewswire.com - February 26 at 7:00 AMSkye Bioscience to Present at Oppenheimer Investor Conferencefinance.yahoo.com - February 7 at 10:27 AMBuy Rating Affirmed for Skye Bioscience on Strong Drug Pipeline and Financial Healthmarkets.businessinsider.com - February 6 at 2:24 PMSkye Bioscience Announces Private Placement Detailsmsn.com - January 30 at 12:18 PMSkye Bioscience Strikes Deal for $50M Capital Boostmsn.com - January 30 at 12:18 PMSkye Bioscience announces $50M private placementmsn.com - January 29 at 8:39 AMSkye Bioscience Announces $50.25 Million Private Placement Equity Financingfinance.yahoo.com - January 29 at 8:39 AMGlobal Cannabis Odyssey: Ontario Expansion, Australian Exports And Innovations In Africamsn.com - December 11 at 10:24 PMSkye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimabfinance.yahoo.com - December 11 at 7:22 AMSkye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africafinance.yahoo.com - December 5 at 8:19 AMSkye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summitfinance.yahoo.com - November 21 at 9:16 AMSkye McAlpine’s easy one-tray dinner recipesthetimes.co.uk - November 20 at 11:54 PMMatthew Perry's ex co-star Ione Skye shares heartbreaking last texts with Friends actormirror.co.uk - November 10 at 9:37 AMSkye Bioscience Inc Ordinary Shares SKYEmorningstar.com - November 8 at 12:24 AMSkye Bioscience posts early-stage data for glaucoma therapymsn.com - October 26 at 9:57 AMSkye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucomafinance.yahoo.com - October 25 at 7:33 AMCORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"finance.yahoo.com - October 20 at 8:59 AMSkye McAlpine’s cakes with carrot, sweet potato and pumpkinthetimes.co.uk - October 10 at 9:14 AMHeritage award for 89-year-old Skye ferry crossingbbc.com - October 1 at 8:15 AMSkye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trialfinance.yahoo.com - September 27 at 7:36 AMSkye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 8:08 AMSkye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conferencefinance.yahoo.com - August 14 at 9:50 AMSkye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsionfinance.yahoo.com - July 13 at 10:00 AMSkye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trialmsn.com - July 6 at 11:34 AMIsle of Skyetravel.usnews.com - June 9 at 8:32 AMSkye Bioscience to Present at LD Micro Invitational XIIIfinance.yahoo.com - June 5 at 8:25 AMSkye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsionfinance.yahoo.com - May 15 at 9:14 AMSkye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - April 29 at 7:41 PMSkye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonistfinance.yahoo.com - April 27 at 7:05 AMShort Volatility Alert: Skye Biosciencemsn.com - April 19 at 1:47 PMSkye Bioscience, Inc.: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsionfinanznachrichten.de - April 4 at 9:07 AMSkye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsionfinance.yahoo.com - April 4 at 9:07 AMSkye Bioscience, Inc.: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journalfinanznachrichten.de - April 3 at 9:46 AM Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Have You Seen Elon’s New A.I. Device? (Picture Inside) (Ad)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast... This strange new device to protect us against that A.I. threat... SKYE Media Mentions By Week SKYE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼0.000.33▲Average Medical News Sentiment SKYE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼00▲SKYE Articles Average Week Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GLSI News SCPH News AEON News CAPR News CRVO News PRQR News IVA News GOSS News ANVS News ACET News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
